Features
Artificial Intelligence as a Tool for Diagnosing and Monitoring Glaucoma
AI offers hope for easing the health-care burden in glaucoma.
By Meghana Kalavar, Sabita M. Ittoop, MD, MALIK KAHOOK, M.D.
A Stepwise Approach to Cases on the Angle-closure Spectrum
Treatment can prevent progression and vision loss.
By Ian Conner, MD, PhD
Detection of Apoptosing Retinal Cells Artificial Intelligence Technology in Glaucoma and AMD
This tool has promising applications in early detection.
By Radhika Pooja Patel, MBBS, BSc, DTMH, Paolo Corazza, MD, FEBO, Maria Francesca Cordeiro, MD, PhD
Prioritizing Quality of Life for Glaucoma Patients With Ab-interno Canaloplasty
The glaucoma treatment paradigm is shifting from long-term use of topical medications to restoring natural outflow.
By Mahmoud A. Khaimi, MD
Web Exclusives
Reversing Vision Loss With Neuromodulation
Numerous candidates could protect or restore vision after optic nerve injury.
By Julie Y. Cho, MD, PhD, Jeffrey L. Goldberg, MD, PhD
A Case of a Young Man With Angle Closure Glaucoma, Plateau Iris, and Pilocarpine Intolerance
Clear lens exchange and ECP/ECPL offer a new level of freedom.
By Brian A. Francis, MD, MS
Departments
From the Editor: Glaucoma's Next Big Opportunity
By Nathan M. Radcliffe, MD
Product Spotlight: The First Digital SLT-YAG Platform Debuts
Device offers enhanced imaging capabilities and automatically integrates with EMRs.
By Karen Appold, contributing writer
News
iTrack Effective in Standalone and Combination Procedures
By Jerry Helzner, contributing editor
Ivantis Releases 5-year Data on Hydrus Microstent
By Jerry Helzner, contributing editor
Patients Report iStent inject Improved Quality of Life
By Jerry Helzner, contributing editor
New World Medical Launches Goniotomy Tool
By Jerry Helzner, contributing editor
Iridex and Topcon Form Strategic Collaboration
By Jerry Helzner, contributing editor
COAST Trial to Assess Annual Low-energy SLT
By Jerry Helzner, contributing editor
OHTS 20-year Follow-up Data Published
By Jerry Helzner, contributing editor
European Glaucoma Society Accepts Laser as First-line Treatment
By Jerry Helzner, contributing editor
Review of iStent Devices in Standalone Procedures
By Jerry Helzner, contributing editor
AAO Identifies OCTA Role in Diagnosing OAG
By Jerry Helzner, contributing editor
New Genetic Links to Glaucoma Identified
By Jerry Helzner, contributing editor
Characteristics of First-appointment “No Shows”
By Jerry Helzner, contributing editor
Sight Sciences’ OMNI System Receives Expanded Indications
By Jerry Helzner, contributing editor
Endophthalmitis Associated With Glaucoma Drainage Implants
By Jerry Helzner, contributing editor
Drug-eluting Contact Lens Promising for Glaucoma
By Jerry Helzner, contributing editor
Early Phaco Deemed Most Effective for APAC
By Jerry Helzner, contributing editor
Wicks Have Mixed Results in Nonvalved Drainage Devices
By Jerry Helzner, contributing editor
Virtual Reality Perimeter Excels in Study
By Jerry Helzner, contributing editor
Fewer Serious Vision Problems for Older Americans
By Jerry Helzner, contributing editor
Normal-tension Glaucoma Linked to Dementia
By Jerry Helzner, contributing editor
Skye Bioscience Studies Synthetic Cannabinoid for Glaucoma
By Jerry Helzner, contributing editor
Citicoline Protects Against Glaucoma in Animal Study
By Jerry Helzner, contributing editor
Stem Cells Made Into Ganglion Cells
By Jerry Helzner, contributing editor
OCTA Artifacts Can Hinder Glaucoma Treatment
By Jerry Helzner, contributing editor